Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614456 · ClinicalTrials.gov registry record · Phase 1
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02614456 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 26 participants.
The verdict
NCT02614456, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a phase I study of combination immunotherapy with IFN-γ and the PD-1 inhibitor nivolumab in patients with advanced solid tumors who have progressed on at least one prior systemic therapy, which may include prior immunotherapy.
Interventions
- DRUG interferon-gamma and nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-12-11 |
| Est. Completion | 2019-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614456
The ClinicalTrials.gov registry entry for NCT02614456 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which interferon-gamma and nivolumab is the first listed.
NCT02614456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614456 about?
NCT02614456 is a clinical study titled "Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors". This is a phase I study of combination immunotherapy with IFN-γ and the PD-1 inhibitor nivolumab in patients with advanced solid tumors who have progressed on at least one prior systemic therapy, which may include prior immunotherapy.
What is the current status of trial NCT02614456?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2015-12-11. Estimated completion is 2019-06-12.
What interventions are being tested in trial NCT02614456?
The interventions under investigation include: interferon-gamma and nivolumab (DRUG).
Who is sponsoring clinical trial NCT02614456?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.